Genomic BRCA and Extensive ovArian Cancer Testing

  • STATUS
    Recruiting
  • End date
    Dec 3, 2029
  • participants needed
    32
  • sponsor
    ARCAGY/ GINECO GROUP
Updated on 3 February 2021
Investigator
Aurélie CHABANON, PhD.
Primary Contact
Institut de Canc rologie Lucien Leuwirth (0.0 mi away) Contact
+176 other location
cancer
carcinoma
cancer chemotherapy
ovarian cancer
formalin-fixed paraffin-embedded
cancer of the ovary

Summary

This is a prospective observational French multicenter cohort in patients with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014). The objective is to constitute a clinico-biological database that allows to correlate clinical and progressive features of ovarian cancer patients based on tumor genomics and molecular detected abnormalities.

Details
Condition Fallopian Tube Cancer, Peritoneal Cancer, Ovarian Epithelial Cancer, Epithelial Ovarian Cancer, Primary Peritoneal Cavity Cancer, Epithelial Ovarian Carcinoma, ovarian epithelial carcinoma, carcinoma of the ovary, fallopian tube cancers
Clinical Study IdentifierNCT04027868
SponsorARCAGY/ GINECO GROUP
Last Modified on3 February 2021

Eligibility

Yes No Not Sure

Inclusion Criteria

Patient older than 18 years
Patient with ovarian and/or primitive peritoneal and/or fallopian tubes carcinoma, histologically confirmed, with an advanced stage at diagnosis (stage III to IV FIGO 2014)
Patient in first line therapy
Available tumor sample fixed in formalin and included in paraffin (FFPE)
in pre-chemotherapy, insofar as possible
having a sufficient tumor surface, with a final cellularity of at least 20%
Identification of a molecular genetics' cancer platform participant in GREAT and an onco-geneticists team working with the investigator team
Patient consenting her data to be collected and submitted through an automated processing
Patient beneficiary from the French social security

Exclusion Criteria

Patient with a mucinous ovarian carcinoma
Patient pregnant or breastfeeding
Patient under legal protection (guardianship or court order) or unable to consent
Clear my responses

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note